International Stem Cell Corp. (ISCO): Benefits of Stem Cells Outlined in Israel/California Collaboration
In a recent article on the Jewish Journal website (https://dtn.fm/DhxK8), doctors, dignitaries and officials representing Israel and California convened at Cedars-Sinai Medical Center on February 8, 2016, to witness the signing of an agreement between Israel’s Ministry of Science and the California Institute for Regenerative Medicine (CIRM) to collaborate on stem cell research. It follows a 2014 Memorandum of Understanding to promote collaboration and innovation between Israel and California.
“Stem cell research is a cutting-edge field full of promise and opportunity. Who better to forge new ground together than the State of Israel and the State of California?” Israeli Minister of Science, Technology and Space Ofir Akunis said in the article. “Both are hotbeds of innovation, medical research and technological invention and have a strong commitment to science as a means to improve the lot of all humanity … creating a brighter future for us all.”
International Stem Cell Corp. (OTCQB: ISCO) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. The company’s stem cells present superior immune matching capabilities and can be used in millions of people, regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
Stem cells are the future of medicine. Companies like International Stem Cell Corp. are on the front lines of this invaluable research, constantly looking for new ways stem cells can improve our quality of life by treating and eliminating diseases of the central nervous system (i.e. Parkinson’s disease), the liver, and the eye. The technology is getting better every day, and more people are coming around to at least giving it a look. The company has an ethical and moral purpose along with the potential to capitalize on a huge revenue stream.
The combined direct and indirect costs of Parkinson’s disease (PD), including treatment, social security payments and lost income from inability to work, is estimated to be nearly $25 billion per year in the U.S. alone. Medication costs for an individual person with PD average $2,500 a year, and therapeutic surgery can cost up to $100,000 dollars per patient.
For more information, visit www.internationalstemcell.com
QualitySPlease read full disclaimers at https://disclaimer.missionir.comtocks.com